A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 576
- Registration Number
- NCT04270747
- Locations
- 🇺🇸
Sabates Eye Center, Leawood, Kansas, United States
🇺🇸Retina Associates New Orleans, Metairie, Louisiana, United States
🇺🇸The Retina Care Center, Baltimore, Maryland, United States
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 470
- Registration Number
- NCT04221542
- Locations
- 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
- Conditions
- ASCVD
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 752
- Registration Number
- NCT04197453
- Locations
- 🇨🇦
Discovery Clinical Services Ltd, Victoria, British Columbia, Canada
🇺🇸The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
- Conditions
- Osteoporosis
- Interventions
- Drug: PlaceboBiological: Denosumab
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT03822078
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 595
- Registration Number
- NCT03721172
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States
🇺🇸MedaPhase INC, Newnan, Georgia, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma(DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT03571828
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT03541369
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen Campus Grosshadern, Muenchen, Germany
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
- Conditions
- Psoriasis
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT03539419
- Locations
- 🇪🇸
Complejo Hospitalario de Jaén, Jaen, Andalucía, Spain
🇪🇸Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain
🇪🇸Hospital General de Alicante, Alicante, Comunidad Valenciana, Spain
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
- Conditions
- Chronic Migraine or Episodic Migraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 343
- Registration Number
- NCT03238781
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 124
- Registration Number
- NCT03097003
- Locations
- 🇧🇪
Ste Elisabeth - Namur, Namur, Belgium
🇧🇪CH Bois Abbaye-Hesbaye, Seraing, Belgium
🇧🇪Private Practice Lede, Lede, Belgium